Bicycle Therapeutics Updates Filing for $80 Million IPO

May 14, 2019

The company plans to offer 4,333,333 American Depositary Shares and raise a maximum $79,733,328. Bicycle has applied to trade trade on the NASDAQ Global Market under the symbol "BCYC."

Bicycle is a clinical-stage biopharmaceutical company developing a novel class of medicines, which they refer to as  Bicycles. Bicycles  are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches.

Though much of the press about Bicycle's potential has been in the oncology arena, the company is also developing therapies outside of oncology. It has partnerships with a number of companies (including AstraZeneca, and Sanofi) to utilize its novel medicines to treat a number of diseases.

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.